Intervention Review

You have free access to this content

Endothelin receptor antagonists for pulmonary arterial hypertension

  1. Chao Liu1,*,
  2. Junmin Chen2,
  3. Yanqiu Gao1,
  4. Bao Deng1,
  5. Kunshen Liu1

Editorial Group: Cochrane Airways Group

Published Online: 28 FEB 2013

Assessed as up-to-date: 12 JAN 2012

DOI: 10.1002/14651858.CD004434.pub5


How to Cite

Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD004434. DOI: 10.1002/14651858.CD004434.pub5.

Author Information

  1. 1

    The First Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China

  2. 2

    The First Affiliated Hospital of Fujian Medical University, Department of Hematology and Rheumatology, Fuzhou, Fujian Province, China

*Chao Liu, The First Hospital of Hebei Medical University, Donggang Road, Shijiazhuang, Hebei Province, 050031, China. dr_chaoliu@yahoo.com.cn. lcwv@sohu.com.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 28 FEB 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 1 Change from baseline in six-minute walk.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 2 Proportion of patients with improved functional class.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 3 Proportion of patients with deteriorated functional class.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 4 Change from baseline in Borg dyspnoea index.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 5 Mortality.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 6 Change from baseline in mean pulmonary artery pressure.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 7 Change from baseline in pulmonary vascular resistance.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 8 Change from baseline in cardiac Index.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 9 Hepatic toxicity.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Endothelin receptor antagonists versus sildenafil, Outcome 1 Six-minute walk.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Endothelin receptor antagonists versus sildenafil, Outcome 2 Symptoms.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Endothelin receptor antagonists versus sildenafil, Outcome 3 Mortality.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Endothelin receptor antagonists versus sildenafil, Outcome 4 Cardiac Index.